Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 15/20 | 1.00 |
| ▸ | CACNB1 | Q02641 | 15/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 12/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 10/20 | 1.00 |
| ▸ | CACNA1A | O00555 | 4/20 | 0.80 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.72 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5264964 | 0.92 | CACNA2D1 (0.85) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL5267690 | 0.89 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL13701482 | 0.85 | CACNA2D1 (0.74) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| Z160 SCHEMBL4180792 | 0.85 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL5265070 | 0.82 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4179716 | 0.81 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4157504 | 0.81 | SLC6A9 (0.69) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4139317 | 0.81 | SLC6A9 (0.69) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL29379324 | 0.81 | SLC6A9 (0.69) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A | |
| SCHEMBL4139313 | 0.81 | SLC6A9 (0.69) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362021-B2 | Method for increasing the bioavailability of benzhydryl piperazine containing compounds | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-01-29 | — | — | US | claimed |
| US-20090312346-A1 | METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-12-17 | — | — | US | claimed |
| EP-2019676-A2 | METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-02-04 | — | — | EP | claimed |
| WO-2007133481-A2 | METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-11-22 | — | — | WO | claimed |
| EP-1610792-B1 | CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES | NEUROMED TECH INC (CA) | 2007-10-10 | — | — | EP | claimed |
| US-8362021-B2 | Method for increasing the bioavailability of benzhydryl piperazine containing compounds | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-01-29 | — | — | US | disclosed |
| US-20090312346-A1 | METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-12-17 | — | — | US | disclosed |
| EP-1610792-B1 | CALCIUM CHANNEL BLOCKERS COMPRISING TWO BENZHYDRIL MOIETIES | NEUROMED TECH INC (CA) | 2007-10-10 | — | — | EP | disclosed |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | NEUROMED TECHNOLOGIES INC. | 2006-04-20 | — | — | US | disclosed |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-23 | — | — | US | disclosed |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | CACNA2D1 41/4885CACNB1 14/4885CACNA1B 4/4885 |
| US-20060084660-A1 | Psychological disorders; analgesics; Parkinson's disease; antiepileptic agents; irritable bowel disorders; antiarrhythmia agents | CACNA1D, CACNA1E, CACNA1B | CACNA2D1 21/4885CACNB1 36/4885CACNA1B 3/4885 |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | CACNA2D1 41/4885CACNB1 14/4885CACNA1B 4/4885 |
| US-20090312346-A1 | METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS | SLC7A1, SLC10A2, SLC10A1 | CACNA2D1 3029/4885CACNB1 1150/4885CACNA1B 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.